Study to Assess Efficacy of AZD1236 in Patients With Cystic Fibrosis

A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II Study to Assess the Efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients With Cystic Fibrosis

The purpose of this study is to determine the effect of AZD1236 in patients with cystic fibrosis (CF) on inflammatory biomarkers in induced sputum, after a treatment period of 4 weeks.

Inclusion Criteria:

• Provision of informed consent prior to any study specific procedures
• Have a clinical diagnosis of cystic fibrosis with an FEV1 >40% of predicted normal
• Be able to comply with induced sputum procedure
• post-menopausal surgically sterile female (total hysterectomy and /or bilateral total oophorectomy)

Exclusion Criteria:

• Concomitant diagnosis of significant pulmonary disease other than CF-related lung disease, including symptomatic asthma and allergic bronchopulmonary aspergillosis
• Treatment with any immunomodulatory agents within 8 weeks prior to Visit 2
• Known to be infected with Burkholderia cepacia